Absence of zidovudine resistance in anti retroviral-naive patients following zidovudine/lamivudine/protease inhibitor combination therapy: Virological evaluation of the AVANTI 2 and AVANTI 3 studies

AIDS

Volumn 14, Issue 9, 2000, Pages 1195-1201

  Maguire, Michael ^a   Gartland, Martin ^a   Moore, Sarah ^a   Hill, Andrew ^a   Tisdale, Margaret ^a   Harrigan, Richard ^b   Kleim, Jörg Peter ^a   Clumeck, N ^c   Cooper, D A ^u   Gazzard, B ^s,u   Goebel, F ⁱ   Lange, J ^k   Montaner, J ^d   Reiss, P ^u   Rozenbaum, W ^h   Vella, S ^u   Beveridge, A ^u   Duncombe, C ^u   Gold, J ^u   Haberl, M ^u   Luyts, D ^u   Rachlis, A ^u   Marina, R ^u   Gerstoft, J ^e   Wandall, J H ^e   Elbrond, B ^u   Molina, J M ^f   Pialloux, G ^g   Beauvais, L ^u   Staszewski, S ^j   Bruns, I ^u   Hug, M ^u   Frissen, P H J ^l   Van Der Ende, M E ^u   Bosboom, M ^u   Baas, C ^u   Milazzo, F ^m   Moroni, M ⁿ   Panebianco, R ^u   Clotet, B ^o   Gatell Artigas, Josep María ^p,u   Gonzalez Lahoz, J ^q   Leal, M ^r   Rodriguez Lopo, C ^u   Gandarias, B ^u   Johnson, M ^t   McKinlay, S ^u   Page, V ^u   Watkins, K ^u   Sandstrom, E ^u   Belsey, E ^u   Darbyshire, J ^u   Chodakewitz, J ^u   Isaacs, R ^u   Jonas, L ^u   Meibohm, A ^u   Clendeninn, N ^u   Petersen, A K ^u   Anderson, R ^u   Coughlan, M ^u   Fiddian, P ^u   Larder, B ^u   Millard, J ^u   Patel, K ^u   Athisegaran, R ^u   Hall, L ^u   Shortino, D ^u   Vafidis, I ^u   Yeo, J ^u   more..

^a GLAXOSMITHKLINE   (United Kingdom)

^b BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^c SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^d ST PAUL S HOSPITAL   (Canada)

^e Rigshospitalet   (Denmark)

^f SAINT LOUIS HOSPITAL   (France)

^g Service des Vaccinations   (France)

^h HÔPITAL ROTHSCHILD   (France)

ⁱ LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^j Zentrum der Inneren Medezin der J   (Germany)

^k ACADEMIC MEDICAL CENTER   (Netherlands)

^l ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^m Divisione di Malattie Infettive   (Italy)

ⁿ Istituto di Clinica Malattie Infettive e Tropicale   (Italy)

^o HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^p HOSPITAL CLÍNIC   (Spain)

^q INSTITUTO DE SALUD CARLOS III   (Spain)

^r HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^s CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^t ROYAL FREE HOSPITAL   (United Kingdom)

^u Chelsea and Westminster Hospital ^*

more..

Author keywords

Antiretroviral therapy; Clinical trials; Combination therapy; HIV drug resistance resistance mutations

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATION; PHENOTYPE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTANT;

EID: 0033946694     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200006160-00017     Document Type: Article

References (26)

1. 1. Montaner JSG, Hogg R, Raboud J, Harrigan R, O'Shaughnessy M. Antiretroviral treatment in 1998. Lancet 1998, 352:1919-1922.
2. 2. Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997, 11:F113-F116.
3. 3. Kuritzkes DR, Quinn JB, Benoit SL, et al. Drug resistance and virologic response in NUCA3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated subjects. AIDS 1996, 10:975-981.
4. 4. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of ZDV-3TC combination therapy. Science 1995, 269:696-699.
5. 5. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
6. 6. Condra JH. Virological and clinical implications of resistance to HIV-1 protease inhibitors. Drug Resist Updates 1998, 1: 292-299.
7. 7. Boden D, Markowitz M. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 1998, 42:2775-2783.
8. 8. Mulder J, Resnick R, Saget B, et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997, 35: 1278-1280.
9. 9. Kellam P, Larder BA. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994, 38:23-30.
10. 10. Goebel F on behalf of the AVANTI Study Croup. AVANTI 2. A randomised, double blind comparative trial to evaluate combination antiretroviral regimens for treatment of HIV-1 infection: ZDV/3TC vs ZDV/3TC/indinavir in antiretroviral naive patients. Sixth European Conference on Clinical Aspects of HIV-1 infection. Hamburg, October 1997 [abstract 211].
11. 11. Clumeck N on behalf of the AVANTI Study Croup. AVANTI 3. A randomised, double blind comparative trial to evaluate the efficacy, safety and tolerance of ZDV/3TC vs ZDV/3TC/nelfinavir in antiretroviral naive patients. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, 1998, [abstract 8].
12. 12. Andreoni M, Sarmati L, Nicastri E, et al. Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy. J Med Virol 1998, 56:332-336.
13. 13. Miller V, Phillips A, Rottmann C, et al. Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure. J Infect Dis 1998, 177:1521-1532.
14. 14. Patick AK, Duran M, Cao Y, et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother 1998, 42: 2637-2644.
15. 15. Condra JH, Schleif WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
16. 16. Condra JH, Holder DJ, Schleíf WA, et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
17. 17. Kozal MJ, Shah N, Shen N, et al. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996, 2:753-759.
18. 18. Hertogs K, Kemp S, Bloor S, et al. Patterns of cross-resistance among protease inhibitors in over 1500 clinical HIV-1 isolates. Comparison of genotypic and phenotypic resistance profiles. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, 24-27 June 1998 [abstract 70].
19. 19. Carillo A, Stewart KD, Sham HL. In vitro selection and characterisation of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol 1998, 72:7232-7241.
20. 20. Nillroth U, Vrang L, Markgren PO, et al. Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs. Antimicrob Agents Chemother 1997, 41:2383-2388.
21. 21. Pazhanisamy S, Partaledis JA, Rao BG, Livingston DJ. In vitro selection and characterisation of VX-478 resistant HIV-1 variants. Adv Exp Med Biol 1998, 436:75-83.
22. 22. Zhang YM, Imamichi H, Imamichi T. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate. J Virol 1997, 71:6662-6670.
23. 23. Havlir DV, Petropopoulos CJ, Hellmann NS, et al. Evolution of drug resistance associated with loss of viral suppression in patients treated with indinavir, lamivudine and zidovudine. Second International Workshop on HIV Drug Resistance and Treatment Strategies. Lake Maggiore, Italy, 24-27 June 1998 [abstract 74].
24. 24. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000, 283:229-234.
25. 25. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000, 283:205-211.
26. 26. Ait-Khaled M, Stone C, Amphlett G, et al. M184V significantly delays the emergence of the T215F/Y, D67N, and L210W mutations independently of viral RNA and time on therapy. Seventh European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal, October 23-27, 1999 [abstract 1236].